PubRank

Markus Pfirrmann

Author PubWeight™ 31.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2013 4.50
2 Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011 3.09
3 Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2009 3.07
4 Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007 2.61
5 Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011 2.52
6 Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011 1.65
7 The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. Haematologica 2005 1.58
8 Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004 1.41
9 Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013 1.35
10 Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012 1.27
11 A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib. Haematologica 2009 1.01
12 Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007 0.99
13 Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol 2013 0.98
14 The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. Haematologica 2012 0.89
15 Shedding of the endothelial glycocalyx during cardiac surgery: on-pump versus off-pump coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2009 0.86
16 The EUTOS CML score aims to support clinical decision-making. Blood 2012 0.81
17 The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood 2014 0.80
18 Reply to H. Kantarjian et al. J Clin Oncol 2014 0.79
19 Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol 2014 0.79
20 Clinical trials in chronic myeloid leukemia. Curr Hematol Malig Rep 2012 0.77
21 Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82. Haematologica 2012 0.75
22 A multi-state model approach for prediction in chronic myeloid leukaemia. Ann Hematol 2014 0.75